 |
인쇄하기
취소
|
LG Life Sciences sign a deal to introduce Demomed's Gastric Retention
LG Life Sciences said that it signed an exclusive license agreement with the US-based Depomed Inc. to distribute Metformin Gastric Retention (GR) in Korea.
Depomed filed an US NDA for Metformin GR for use in the treatment of diabetes in April after successful completion of Phase III trial. The company is expected to receive a FDA approval during April of 2005.
By lengthening drug retenti...
Depomed filed an US NDA for Metformin GR for use in the treatment of diabetes in April after successful completion of Phase III trial. The company is expected to receive a FDA approval during April of 2005.
By lengthening drug retenti...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.